Basic mechanisms and regulation of fibrinolysis

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S98-S105

  Longstaff, C ^a   Kolev, K ^b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Fibrin; Fibrinolysis; Plasminogen; Thrombolytic therapy

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 13A; FIBRIN; FIBRINOGEN; HISTONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROUROKINASE; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PROTEIN BINDING;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; DRUG MECHANISM; ERYTHROCYTE; EXTRACELLULAR TRAP; FIBRINOLYSIS; HUMAN; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE FUNCTION; ANIMAL; DRUG EFFECTS; FIBRINOLYTIC THERAPY; METABOLISM;

ANIMALS; FIBRIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN; PLASMINOGEN ACTIVATORS; PROTEIN BINDING; THROMBOLYTIC THERAPY;

EID: 84931420701     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12935     Document Type: Review

References (63)

1. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-9.
2. Horrevoets AJG, Pannekoek H, Nesheim ME. A steady-state template model that describes the kinetics of fibrin- stimulated. J Biol Chem 1997; 272: 2183-91.
3. de Vries C, Veerman H, Nesheim ME, Pannekoek H. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants. Thromb Haemost 1991; 65: 280-5.
4. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003; 89: 409-19.
5. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-56.
6. Longstaff C, Williams S, Thelwell C. Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem 2008; 6: 212-23.
7. Ariens RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11(Suppl. 1): 294-305.
8. Stewart RJ, Fredenburgh JC, Rischke JA, Bajzar L, Weitz JI. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator. J Biol Chem 2000; 275: 36612-20.
9. Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink MF. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem 2007; 282: 2229-36.
10. Gebbink MF. Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. J Thromb Haemost 2011; 9(Suppl. 1): 174-81.
11. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996; 271: 2133-8.
12. Sakharov DV, Rijken DC. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995; 92: 1883-90.
13. Longstaff C, Thelwell C, Williams SC, Silva MM, Szabo L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117: 661-8.
14. Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA). J Thromb Haemost 2012; 10: 2354-60.
15. Law RH, Caradoc-Davies T, Cowieson N, Horvath AJ, Quek AJ, Encarnacao JA, Steer D, Cowan A, Zhang Q, Lu BG, Pike RN, Smith AI, Coughlin PB, Whisstock JC. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012; 1: 185-90.
16. Xue Y, Bodin C, Olsson K. Crystal structure of the native plasminogen reveals an activation-resistant compact conformation. J Thromb Haemost 2012; 10: 1385-96.
17. Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-904.
18. Gurewich V. Fibrinolytic mechanisms of tPA, prouPA, mutant prouPA and their implications for therapeutic thrombolysis. Cardiovasc Eng Technol 2013; 4: 328-38.
19. Dejouvencel T, Doeuvre L, Lacroix R, Plawinski L, Dignat-George F, Lijnen HR, Angles-Cano E. Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood 2010; 115: 2048-56.
20. Cook SM, Skora A, Gillen CM, Walker MJ, McArthur JD. Streptokinase variants from Streptococcus pyogenes isolates display altered plasminogen activation characteristics - implications for pathogenesis. Mol Microbiol 2012; 86: 1052-62.
21. Bhattacharya S, Ploplis VA, Castellino FJ. Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination. J Biomed Biotechnol 2012; 2012: 482096.
22. Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost 2007; 5: 804-11.
23. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279: 13333-9.
24. Nesheim M, Bajzar L. The discovery of TAFI. J Thromb Haemost 2005; 3: 2139-46.
25. Foley JH, Kim PY, Mutch NJ, Gils A. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. J Thromb Haemost 2013; 11(Suppl. 1): 306-15.
26. Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 1: 2000-7.
27. Anand K, Pallares I, Valnickova Z, Christensen T, Vendrell J, Wendt KU, Schreuder HA, Enghild JJ, Aviles FX. The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa. J Biol Chem 2008; 283: 29416-23.
28. Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrika W, Meijers JC, Huizinga EG. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood 2008; 112: 2803-9.
29. Mosesson MW, Finlayson JS, Umfleet RA, Galanakis D. Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates. J Biol Chem 1972; 247: 5210-9.
30. Koehn JA, Hurlet-Jensen A, Nossel HL, Canfield RE. Sequence of plasmin proteolysis at the NH2-terminus of the b beta-chain of human fibrinogen. Anal Biochem 1983; 133: 502-10.
31. Marder VJ, Shulman NR, Carroll WR. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 1969; 244: 2111-9.
32. Kirschbaum NE, Budzynski AZ. A unique proteolytic fragment of human fibrinogen containing the A alpha COOH-terminal domain of the native molecule. J Biol Chem 1990; 265: 13669-76.
33. Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999; 274: 5201-12.
34. Varju I, Tenekedjiev K, Keresztes Z, Pap AE, Szabo L, Thelwell C, Longstaff C, Machovich R, Kolev K. Fractal kinetic behavior of plasmin on the surface of fibrin meshwork. Biochemistry 2014; 53: 6348-56.
35. Kovacs A, Szabo L, Longstaff C, Tenekedjiev K, Machovich R, Kolev K. Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin. Thromb Res 2014; 133: 80-7.
36. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
37. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813-26.
38. Bridge KI, Philippou H, Ariens R. Clot properties and cardiovascular disease. Thromb Haemost 2014; 112: 901-8.
39. Lam WA, Chaudhuri O, Crow A, Webster KD, Li TD, Kita A, Huang J, Fletcher DA. Mechanics and contraction dynamics of single platelets and implications for clot stiffening. Nat Mater 2011; 10: 61-6.
40. Varju I, Sotonyi P, Machovich R, Szabo L, Tenekedjiev K, Silva MM, Longstaff C, Kolev K. Hindered dissolution of fibrin formed under mechanical stress. J Thromb Haemost 2011; 9: 979-86.
41. Brown AE, Litvinov RI, Discher DE, Purohit PK, Weisel JW. Multiscale mechanics of fibrin polymer: gel stretching with protein unfolding and loss of water. Science 2009; 325: 741-4.
42. Bagoly Z, Koncz Z, Harsfalvi J, Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res 2012; 129: 382-7.
43. Hethershaw EL, Cilia La Corte AL, Duval C, Ali M, Grant PJ, Ariëns RAS, Philippou H. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014; 12: 197-205.
44. Duval C, Allan P, Connell SD, Ridger VC, Philippou H, Ariens RA. Roles of fibrin alpha- and gamma-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb Haemost 2014; 111: 842-50.
45. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariens RA. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115: 3980-8.
46. Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood 2011; 117: 6371-4.
47. Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mutch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood 2014; 124: 3982-90.
48. Matveyev M, Domogatsky SP. Penetration of macromolecules into contracted blood clot. Biophys J 1992; 63: 862-3.
49. Carvalho FA, Connell S, Miltenberger-Miltenyi G, Pereira SV, Tavares A, Ariens RA, Santos NC. Atomic force microscopy-based molecular recognition of a fibrinogen receptor on human erythrocytes. ACS Nano 2010; 4: 4609-20.
50. Aleman MM, Byrnes JR, Wang JG, Tran R, Lam WA, Di Paola J, Mackman N, Degen JL, Flick MJ, Wolberg AS. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014; 124: 3590-600.
51. Cines DB, Lebedeva T, Nagaswami C, Hayes V, Massefski W, Litvinov RI, Rauova L, Lowery TJ, Weisel JW. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 2014; 123: 1596-603.
52. Wohner N, Sotonyi P, Machovich R, Szabo L, Tenekedjiev K, Silva MM, Longstaff C, Kolev K. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol 2011; 31: 2306-13.
53. Wautier MP, Heron E, Picot J, Colin Y, Hermine O, Wautier JL. Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion. J Thromb Haemost 2011; 9: 1049-55.
54. Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood 2012; 120: 3837-45.
55. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123: 2768-76.
56. Longstaff C, Varju I, Sotonyi P, Szabo L, Krumrey M, Hoell A, Bota A, Varga Z, Komorowicz E, Kolev K. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. J Biol Chem 2013; 288: 6946-56.
57. Diamond SL. Systems biology of coagulation. J Thromb Haemost 2013; 11(Suppl. 1): 224-32.
58. Bannish BE, Keener JP, Woodbury M, Weisel JW, Fogelson AL. Modelling fibrinolysis: 1D continuum models. Math Med Biol 2014; 31: 45-64.
59. Bannish BE, Keener JP, Fogelson AL. Modelling fibrinolysis: a 3D stochastic multiscale model. Math Med Biol 2014; 31: 17-44.
60. Bannish B, Kolev K, Longstaff C. Experimental validation of a stochastic multiscale model of fibrinolysis. J Thromb Haemost 2015. Abstract: submitted ISTH 2015 Congress.
61. Novokhatny VV, Ingham KC, Medved LV. Domain structure and domain-domain interactions of recombinant tissue plasminogen activator. J Biol Chem 1991; 266: 12994-3002.
62. Bringmann P, Gruber D, Liese A, Toschi L, Kratzchmar J, Schleuning WD, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270: 25596-603.
63. Stewart RJ, Fredenburgh JC, Weitz JI. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J Biol Chem 1998; 273: 18292-9.